Semaglutide Clinics in Seattle

The Seattle question isn’t access — it’s which door

If you’re in Seattle and thinking about semaglutide, start by setting aside the worry that dominated 2023 and 2024. Ozempic and Wegovy are FDA-approved. Both came off the FDA shortage list in early 2025. The oral Wegovy tablet launched in January 2026. Any pharmacy in King, Pierce, or Snohomish County can fill a valid prescription, and the manufacturer’s own direct-to-patient pharmacy ships nationally. Supply is no longer the obstacle it once was.

What replaces it is a quieter, more confusing problem: in Washington you almost certainly have some form of coverage, but whether that coverage pays for weight-loss semaglutide depends entirely on which door you happen to be standing in. That’s true everywhere to a degree, but Washington makes it unusually stark, because the state has done more than most to standardize health coverage — and yet the part that matters most to a GLP-1 shopper is the part it left alone.

Note: Throughout this page, “semaglutide for weight loss” means Wegovy (and the oral Wegovy tablet). The same molecule prescribed as Ozempic for type 2 diabetes is covered far more readily across nearly every door below. The indication written on the prescription is the single biggest lever on whether you pay a copay or a four-figure annual bill — and it has to be the indication an honest workup actually supports, not one chosen to unlock coverage.

Washington standardized the plan, not the formulary

Washington built one of the most consumer-friendly individual-market systems in the country. Through the state’s Healthplanfinder exchange, almost all plans are now Cascade Care plans, which use a standard benefit design: deductibles, copays, and out-of-pocket limits are fixed at each metal level so you can compare carriers “apples to apples.” On top of that sits Cascade Select, the nation’s first public option, and Cascade Care Savings, state-funded premium help. By 2026 roughly nine in ten exchange enrollees were in Cascade Care plans.

Here’s the catch that trips up GLP-1 shoppers. The standardization covers cost-sharing — how much you pay at the pharmacy counter once a drug is covered. It does not standardize the formulary — which drugs are covered and what gates sit in front of them. That’s still set carrier by carrier. So two Cascade Gold plans from two different insurers can have identical deductibles and identical out-of-pocket maximums, and still give you opposite answers on weight-loss semaglutide: one covers it after a prior authorization, another excludes weight-loss use entirely while covering the diabetes indication.

The practical lesson: in Seattle, the metal tier tells you what you’ll pay if a drug is covered. It tells you nothing about whether weight-loss semaglutide is covered. For that, you have to open the specific carrier’s drug list and read the entry. The friendly “apples to apples” framing the state worked hard to create stops exactly where your question begins.

Your coverage doors, one by one

Apple Health (Washington Medicaid)

This is where Washington genuinely stands out. Apple Health is one of only about 13 state Medicaid programs that cover a GLP-1 for obesity as of January 2026 — and several states (California, Pennsylvania, New Hampshire, South Carolina) dropped that coverage for 2026, so Washington holding it is meaningful. Coverage comes with conditions: on the 2026 Apple Health drug list, the weight-loss agents are flagged non-preferred, which usually means you must try, or document a real intolerance to, preferred anti-obesity options before the plan pays for Wegovy; you’ll need to meet BMI and documented-lifestyle criteria; and authorizations are typically time-limited and reauthorized. If your prescriber is treating type 2 diabetes, semaglutide-as-Ozempic is covered on its own diabetes pathway. The takeaway for an Apple Health member: the door is open, but it’s a gated door, and a provider who actually completes the prior-authorization paperwork is doing real work on your behalf.

Cascade Care and other commercial exchange plans

As above: standardized cost-sharing, carrier-specific formulary. The two largest commercial carriers most Puget Sound residents encounter, Premera and Regence, run prior-authorization protocols for weight-loss GLP-1s that commonly require several months of documented lifestyle intervention before approval; some self-funded employer plans extend that window further. None of that is visible from the metal tier. Pull the carrier’s formulary, search the drug, and read whether weight-loss use is covered and what the PA criteria are before you commit to a plan or a clinic.

Kaiser Permanente Washington

Kaiser is a closed, integrated system — insurer, medical group, and pharmacy in one — so two things follow. First, its formulary tends to steer weight-loss patients to Wegovy first through its own pharmacies, which can be efficient if you’re a member. Second, because it’s a closed network, an outside telehealth clinic generally can’t write a prescription your Kaiser benefit will pay for at the covered price. If you’re a Kaiser member, your most affordable path usually runs through Kaiser’s own weight-management process, not a separate cash clinic.

PEBB / SEBB Uniform Medical Plan (public and school employees)

If you work for the state, a public university, or a Washington school district, you may be on the Uniform Medical Plan. As a rule, UMP does not cover anti-obesity medications for weight loss; it covers GLP-1s for diabetes. The Health Care Authority modeled what adding obesity coverage would cost in a 2024 legislative analysis, but absent legislative action it remains uncovered. So a public-sector worker in Seattle can sit behind a generous plan and still find weight-loss semaglutide isn’t on it. Confirm your current plan year — this is one of the doors most likely to surprise people who assume “good plan” means “covers everything.”

Large self-insured private employers

Seattle’s signature employers — Microsoft, Amazon, Boeing, Starbucks, Costco — mostly run self-funded plans. That means the employer, not the carrier whose name is on your card, decides whether weight-loss GLP-1s are covered, and many large employers have been tightening that benefit through 2025–2026 with prior authorization, BMI thresholds, step therapy, or program-enrollment requirements. A plan “administered by” a national carrier is not the same as that carrier’s standard plan. Read your specific employer’s drug list for this plan year; the 2024 answer is not necessarily the 2026 answer.

Medicare

Standard Part D still can’t cover semaglutide for weight loss alone (it covers the diabetes and cardiovascular indications). The temporary Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027, offering eligible Part D members Wegovy for a flat $50/month copay — but that copay sits outside the Part D benefit, so it doesn’t count toward your deductible or the annual out-of-pocket cap, and the low-income subsidy doesn’t apply to it. As of CMS’s May 2026 update, the longer-term BALANCE model’s Medicare piece was delayed and the Bridge extended through 2027. Seattle isn’t a Medicare-majority metro, so this is a real option for older residents rather than the centerpiece — and the detailed mechanics are worth reviewing separately.

What it costs if you’re paying cash

The most important thing to understand about cash pricing is that the drug price is national — there is no special Seattle rate, and a clinic implying otherwise is a flag. Through the manufacturer’s self-pay program, the oral Wegovy tablet starts around $149/month at the lowest doses (the cheapest legitimate brand entry point), the self-pay injection runs roughly $199/month as a new-patient introductory price and about $349/month standard, the higher-dose pen is a little more, and the list price sits near $1,349/month. A commercial savings card can bring some patients to as little as about $25/month, but government beneficiaries — Medicaid, Medicare, TRICARE — are excluded, and the manufacturer’s patient-assistance program can provide brand product free to qualifying uninsured patients.

What a Seattle clinic does vary is the wrapper around the drug: the visit fee, labs, and any membership. High local cost of living tends to push that wrapper up, not the molecule. So when you compare clinics, separate the drug price from the clinic fee and ask for the all-in annual number, because semaglutide is a chronic treatment, not a one-month purchase.

The compounded-semaglutide question in Seattle

Washington has an active cash market for compounded semaglutide, often sold as a low monthly subscription. During the shortage that made sense; in mid-2026 it deserves scrutiny. The shortage resolved in early 2025. In April 2026 the FDA proposed removing semaglutide from the 503B bulk-compounding list — a proposal that is not final and is not a reclassification of anything. Narrow, patient-specific 503A compounding remains lawful, but the FDA has been explicit that affordability or convenience alone is not a clinical justification for it.

Seattle has a particular reason to pause: it’s one of the places where the rationale is doubly weak. Many residents have either a covering Apple Health lane or access to discounted brand cash, so the affordability argument for compounding largely evaporates here. A compounded vial of unverified concentration is not interchangeable with a brand pen, and it ships through the same temperature-sensitive cold chain — something to keep in mind for shipments to the islands, the Peninsula, or over the Cascades in winter. If a clinic’s default for everyone is a cheap compounded subscription, the fair question is: why this product, for me specifically, and from which pharmacy?

Telehealth vs in-person on Puget Sound

Washington is one of the more telehealth-permissive states, and the first visit can run entirely over video. For a stable, monitored chronic medication like semaglutide, a good telehealth program can be every bit as legitimate as an in-person clinic — the format isn’t the risk. What matters is that the prescriber is licensed for where you physically are, that there’s a real evaluation rather than a checkout form, and that follow-up is actually staffed. Density isn’t quality: a storefront in Bellevue or downtown isn’t automatically better medicine than a telehealth visit with a thorough clinician. Washington’s specific licensing rules — who may legally prescribe to a patient sitting in Washington, and how to verify a clinician’s license — are covered on our general Seattle peptide clinics page and the Washington state guide; verify the individual prescriber, not the brand’s logo.

How to vet a Seattle semaglutide provider

For an approved drug in a coverage-complicated state, the checklist is less about “can they get it” and more about whether they’ll do real medicine and help you use your coverage:

• A real evaluation, including the standard contraindication screen (personal or family history of medullary thyroid carcinoma or MEN-2) — not a one-page questionnaire.
• A verifiable Washington-licensed prescriber you can confirm through the state’s credential search.
• Brand-versus-compounded transparency, including the name of the pharmacy filling your prescription.
• Coverage help, not a cash upsell — a clinic that figures out which of your doors pays, runs the prior authorization, and documents for reauthorization is worth more than one that defaults everyone to a membership.
• Real follow-up, because Apple Health and many commercial plans require documented progress to keep covering the drug, and because this is long-term treatment.
• A provider who will sometimes say no — to cosmetic low-BMI requests, or to inventing an indication to unlock coverage, which is fraud, not a workaround.

Get those right and the Seattle-specific maze becomes manageable: pick the door that pays, read the actual formulary rather than the metal tier, and choose the provider on follow-up and honesty rather than price or convenience.